A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma

BACKGROUND: Preclinical data suggest some cannabinoids may exert antitumour effects against glioblastoma (GBM). Safety and preliminary efficacy of nabiximols oromucosal cannabinoid spray plus dose-intense temozolomide (DIT) was evaluated in patients with first recurrence of GBM. METHODS: Part 1 was...

Descripción completa

Detalles Bibliográficos
Autores principales: Twelves, Chris, Sabel, Michael, Checketts, Daniel, Miller, Sharon, Tayo, Bola, Jove, Maria, Brazil, Lucy, Short, Susan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039032/
https://www.ncbi.nlm.nih.gov/pubmed/33623076
http://dx.doi.org/10.1038/s41416-021-01259-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039032/
https://www.ncbi.nlm.nih.gov/pubmed/33623076
http://dx.doi.org/10.1038/s41416-021-01259-3

Ejemplares similares